# Beijing VDJBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-vdjbio-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.vdjbio.com
- Latest round: Series C (Jun 6, 2023)
- Investors on record: 11

## About

Based in Beijing, China and established in 2011, Beijing VDJBio Co., Ltd. is a biotechnology company that focuses on the research and development of innovative antibody drugs for autoimmune diseases. Ziqiang Li, the founder and CEO of the company, used to be the director of the Cell Biology Department of Novo Nordisk China R&D Center. In June 2023, the company raised series C funding led by new investor BCT Capital. Other returning investor Lotus Lake Ventures, new investors Beijing Yiyuan Investment Management, Hangzhou Hongcheng Investment Management, Hangzhou Huadian Investment Management Co., Ltd., Liyuan Venture Capital, and an individual investor also participated in the round.

The company's main products include IL-6R antibody and CTLA-4-Ig, etc. CTLA-4-Ig fusion protein is used to inhibit T cell activation. Its products are used in the treatment of autoimmune diseases and inflammation, among other fields.

## Funding rounds

- Series C, Jun 6, 2023 — Lotus Lake Capital, Liyuan Venture Capital, Hangzhou Huadian Investment Management Co., Ltd., BCT Capital, Hongcheng Investment Management, Beijing Yiyuan Investment Management
- Series B, Nov 30, 2020 — Lotus Lake Capital, SDIC Venture Capital, Jiuyo Capital, Tao Capital, Grand Capital
- Series A, Sep 30, 2016 — THG Ventures

## Investors

- THG Ventures (https://capitalatlas.ai/funds/thg-ventures) — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B, Series C
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series B
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series B
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series B
- Grand Capital — Series B
- Liyuan Venture Capital (https://capitalatlas.ai/funds/liyuan-venture-capital) — Series C
- Hangzhou Huadian Investment Management Co., Ltd. — Series C
- BCT Capital (https://capitalatlas.ai/funds/bct-capital) — Series C
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Series C
- Beijing Yiyuan Investment Management — Series C